Pharm Exec 2023：Mike Christel on LinkedIn
Mike Christel on LinkedIn
Withthesalesboomfrom#COVID19productsnowintherear-view,aresettingisunderwayforthoseinPharmExec'slistingofthetop#biopharma ...。其他文章還包含有：「2023PharmExecTop50Companies」、「IndustryPredictionsFor2023」、「January2023」、「June2023」、「PharmExecVIDEOPodcast」、「PharmaceuticalExecutive2023EmergingPharmaLeaders...」、「PharmaceuticalExecutive's2023EmergingPharmaLeaders」、「Pharmaceut...
查看更多 離開網站
2023 Pharm Exec Top 50 Companies
https://www.pharmexec.com
Besides BioNTech and Novavax, other new entrants to the Pharma 50 include Perrigo Company at No. 32, Chugai Pharmaceutical at No. 35, and Incyte ...
Industry Predictions For 2023
https://www.pharmexec.com
Top industry experts weigh in on what the new year holds for the pharma industry. Advertisement. PREDICTION #1: In 2023, the chasm will ...
January 2023
https://www.pharmexec.com
What We Foresee in '23: Pharm Exec's Annual Industry Outlook. January 11, 2023. 43. 01. Exploring the most relevant topics affecting the biopharma industry ...
June 2023
https://www.pharmexec.com
2023 Pharm Exec Top 50 Companies ... With the sales boom from COVID-19 products now in the rear-view, a resetting is underway for those in Pharm ...
Pharm Exec VIDEO Podcast
https://www.pharmexec.com
Pharmaceutical Executive 2023 Emerging Pharma Leaders ...
https://www.pharmexec.com
Join us in celebrating the up-and-coming leaders who are vital to the future of the pharmaceutical and biotech industry.
Pharmaceutical Executive's 2023 Emerging Pharma Leaders
https://www.pharmexec.com
Pharm Exec profiles its 2023 Emerging Pharma Leaders. ... Each year, Pharmaceutical Executive recognizes up-and-coming leaders who are vital to ...
Pharmaceutical Executive
https://www.pharmexec.com
... Executive June 2023 issue in an interactive PDF format. ... Published on: June 5, 2023 ... 2023 Pharm Exec Top 50 Companies.
PharmExec
https://www.pharmexec.com
Teva, Department of Justice Agree to Drug Price Fixing Settlement. August 24, 2023. Pharma company to pay a fine of $225 million over five years.